FDA Approves ROSUVASTATIN CALCIUM — Ascend Laboratories, LLC

On March 21, 2017, Ascend Laboratories, LLC received FDA approval for the ANDA for rosuvastatin calcium, a generic version of the widely used cholesterol-lowering drug. This route-to-market clearance positions Ascend to compete directly with established manufacturers in the $6 billion statin market, likely putting downward pressure on prices and capturing share through its affordable oral formulation.